Abbott Outperforms Danaher as FreeStyle Libre Drives Growth Amid Slumping Biotech Demand
In Q1 2026, Abbott Laboratories (ABT) outpaced Danaher Corporation (DHR), driven by strong performance from its consumer-facing products like the FreeStyle Libre continuous glucose monitor. In contrast, Danaher faced challenges in diagnostics and bioprocessing due to a soft flu season and weak capital spending demand.
Topics: Bioprocessing Equipment Diagnostics Dividend History Medical Devices